These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18305426)

  • 21. Transition Metal-Based Prodrugs for Anticancer Drug Delivery.
    Phillips AMF; Pombeiro AJL
    Curr Med Chem; 2019; 26(41):7476-7519. PubMed ID: 30501593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The application of prodrug-based nano-drug delivery strategy in cancer combination therapy.
    Ge Y; Ma Y; Li L
    Colloids Surf B Biointerfaces; 2016 Oct; 146():482-9. PubMed ID: 27400243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
    Xiao H; Noble GT; Stefanick JF; Qi R; Kiziltepe T; Jing X; Bilgicer B
    J Control Release; 2014 Jan; 173():11-7. PubMed ID: 24511610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
    Yuan Z; Yi X; Zhang J; Cheng S; Zhuo R; Li F
    Chem Commun (Camb); 2013 Jan; 49(8):801-3. PubMed ID: 23235958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation and Delivery of Tetrazine-Responsive Bioorthogonal Prodrugs.
    Wang Y; Zhang C; Wu H; Feng P
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33266075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Finding the optimal balance: challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems.
    Kratz F; Warnecke A
    J Control Release; 2012 Dec; 164(2):221-35. PubMed ID: 22705248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
    Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
    J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment.
    Zhang W; Li C; Shen C; Liu Y; Zhao X; Liu Y; Zou D; Gao Z; Yue C
    Drug Deliv; 2016 Sep; 23(7):2575-2580. PubMed ID: 26056720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyamine-Targeting Gefitinib Prodrug and its Near-Infrared Fluorescent Theranostic Derivative for Monitoring Drug Delivery and Lung Cancer Therapy.
    Song X; Han X; Yu F; Zhang X; Chen L; Lv C
    Theranostics; 2018; 8(8):2217-2228. PubMed ID: 29721074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy.
    Joubert N; Denevault-Sabourin C; Bryden F; Viaud-Massuard MC
    Eur J Med Chem; 2017 Dec; 142():393-415. PubMed ID: 28911823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
    Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
    J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.
    Legigan T; Clarhaut J; Tranoy-Opalinski I; Monvoisin A; Renoux B; Thomas M; Le Pape A; Lerondel S; Papot S
    Angew Chem Int Ed Engl; 2012 Nov; 51(46):11606-10. PubMed ID: 22996951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular targeting with radionuclides: state of the science.
    Britz-Cunningham SH; Adelstein SJ
    J Nucl Med; 2003 Dec; 44(12):1945-61. PubMed ID: 14660721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prodrug approaches for CNS delivery.
    Rautio J; Laine K; Gynther M; Savolainen J
    AAPS J; 2008; 10(1):92-102. PubMed ID: 18446509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prodrugs in site-selective delivery of radiopharmaceuticals.
    Baranowska-Kortylewicz J; Kortylewicz ZP; Hoffman D; Dalrymple GV
    Q J Nucl Med; 1997 Jun; 41(2):127-39. PubMed ID: 9203852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted delivery of a model immunomodulator to the lymphatic system: comparison of alkyl ester versus triglyceride mimetic lipid prodrug strategies.
    Han S; Quach T; Hu L; Wahab A; Charman WN; Stella VJ; Trevaskis NL; Simpson JS; Porter CJ
    J Control Release; 2014 Mar; 177():1-10. PubMed ID: 24398334
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.
    Ye J; Shin MC; Liang Q; He H; Yang VC
    J Control Release; 2015 May; 205():58-69. PubMed ID: 25483423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.
    Puris E; Gynther M; Huttunen J; Auriola S; Huttunen KM
    Eur J Pharm Sci; 2019 Mar; 129():99-109. PubMed ID: 30625368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prodrug strategy for enhancing drug delivery via skin.
    Fang JY; Leu YL
    Curr Drug Discov Technol; 2006 Sep; 3(3):211-24. PubMed ID: 17311566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is prodrug design an approach to increase water solubility?
    Sanches BMA; Ferreira EI
    Int J Pharm; 2019 Sep; 568():118498. PubMed ID: 31301465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.